| SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients" (NCT04033367) | Sanofi | 2019-08-22 |
| A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis (NCT04271514) | RAPT Therapeutics, Inc. | 2019-08-12 |
| Epidemiological Survey and Genetic Analysis of AD Patients in Hong Kong (NCT04154839) | The University of Hong Kong | 2019-07-12 |
| Evaluating the Effect of Bathing Additives in Atopic Dermatitis (NCT04001855) | University of Arizona | 2019-07-01 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (NCT04018027) | Cara Therapeutics, Inc. | 2019-06-29 |
| Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis (NCT03954158) | Pfizer | 2019-06-15 |
| Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis (NCT03614221) | Chang Gung Memorial Hospital | 2019-06-03 |
| Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis (NCT03916081) | Arcutis Biotherapeutics, Inc. | 2019-05-31 |
| A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis (NCT03920852) | Incyte Corporation | 2019-05-30 |
| A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (NCT03952559) | Eli Lilly and Company | 2019-05-24 |
| Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo (NCT04192513) | DermBiont, Inc. | 2019-05-20 |
| Probiotic Lactobacillus Rhamnosus GG for Pediatric Atopic Dermatitis (NCT03863418) | Federico II University | 2019-05-15 |
| Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis (NCT03961529) | Otsuka Pharmaceutical Co., Ltd. | 2019-05-14 |
| Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (NCT03903822) | Pfizer | 2019-05-13 |
| Sensory Nociceptive Nerve Fibers, Key Regulator of Immune Response Type 2 in Atopic Dermatitis (NCT04193670) | University Hospital, Toulouse | 2019-05-07 |
| Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis (NCT03911401) | Otsuka Pharmaceutical Co., Ltd. | 2019-05-07 |
| A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (NCT03542994) | Evelo Biosciences, Inc. | 2019-04-24 |
| Wearable Skin Sensors to Assess Nocturnal Scratch Behavior (NCT03770858) | Northwestern University | 2019-04-18 |
| Skin Microbial Ecology in Atopic Dermatitis (NCT04170244) | University of Rochester | 2019-04-17 |
| A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD) (NCT03921411) | Galderma R&D | 2019-04-09 |
| Evalution the Safety and Efficacy in Atopic Dermatitis Patients (NCT03962387) | Kang Stem Biotech Co., Ltd. | 2019-04-05 |
| Scratch Behavior Under Standard of Care (NCT03898427) | Boston University | 2019-04-04 |
| A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients (NCT03948334) | Novartis Pharmaceuticals | 2019-04-04 |
| Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome (NCT03908970) | Otsuka Pharmaceutical Co., Ltd. | 2019-03-25 |
| A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03864627) | Lakefront Biotherapeutics NV | 2019-03-25 |
| A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis (NCT03809663) | Amgen | 2019-03-15 |
| Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis (NCT03846466) | Kyowa Kirin Co., Ltd. | 2019-02-22 |
| A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03738397) | AbbVie | 2019-02-21 |
| The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis (NCT03775590) | Mayo Clinic | 2019-02-21 |
| The Role of Bacterial Toxins in Human Skin Disease (NCT02910791) | National Jewish Health | 2019-02-20 |
| ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis (NCT03645057) | University of Rochester | 2019-02-20 |
| Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children (NCT03826901) | LEO Pharma | 2019-02-20 |
| JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (NCT03796676) | Pfizer | 2019-02-18 |
| A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT03831191) | Eli Lilly and Company | 2019-02-12 |
| A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis (NCT03747575) | Genentech, Inc. | 2019-02-06 |
| Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis (NCT03824405) | Botanix Pharmaceuticals | 2019-02-04 |
| Intervention in Chronic Pediatric Patients and Their Families. (NCT04476433) | University of Valencia | 2019-02-04 |
| Treatment of Nighttime Pruritus in Atopic Dermatitis (NCT03688464) | University of Nebraska | 2019-02-02 |
| Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK) (NCT03823794) | Momentum Data | 2019-02-01 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis (NCT03646604) | AbbVie | 2019-01-31 |
| Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis (NCT03632174) | BioGaia AB | 2019-01-21 |
| Clinical, Psychological and Genetic Characteristics in Dermatological Patients (NCT03831646) | Astana Medical University | 2019-01-20 |
| Phototherpy Versus Tapwater Iontophoresis for Management of Atopic Dermatitis in Children. (NCT04444726) | Cairo University | 2019-01-20 |
| Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis (NCT03874039) | Northwestern University | 2019-01-15 |
| Investigation of Flare and Remission in Subjects With Atopic Dermatitis (NCT03710044) | LEO Pharma | 2019-01-14 |
| Restoration of Microbiota in Neonates (NCT03928431) | Karolinska Institutet | 2019-01-01 |
| Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. (NCT03725722) | LEO Pharma | 2018-12-28 |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC (NCT03661866) | Target PharmaSolutions, Inc. | 2018-12-21 |
| Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis (NCT03745638) | Incyte Corporation | 2018-12-20 |
| TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis (NCT03745651) | Incyte Corporation | 2018-12-20 |
| Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis (NCT03912259) | Sanofi | 2018-12-19 |
| Monitoring Of Scratch Via Accelerometry In Children (NCT03873220) | Boston University | 2018-12-14 |
| Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (NCT03761537) | LEO Pharma | 2018-12-13 |
| A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis (NCT03775434) | AOBiome LLC | 2018-12-07 |
| Assessment of the Impact of Whole Body Cryostimulation on Skin Physiological Indicators (NCT03761199) | University School of Physical Education, Krakow, Poland | 2018-11-26 |
| Effects of an Anti-TRPM8 in the Atopic Dermatitis Pruritus (NCT03610386) | University Hospital, Brest | 2018-11-21 |
| A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (NCT03733353) | Evelo Biosciences, Inc. | 2018-11-19 |
| A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (NCT03733301) | Eli Lilly and Company | 2018-11-16 |
| A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis (NCT03517566) | Novartis Pharmaceuticals | 2018-11-14 |
| Eczema Reminder and Accountability Program (NCT03735459) | McMaster University | 2018-11-13 |
| Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT03736967) | Regeneron Pharmaceuticals | 2018-11-12 |
| The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients (NCT03667014) | University of California, San Francisco | 2018-11-01 |
| A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03661138) | AbbVie | 2018-10-27 |
| Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis (NCT03703102) | Kyowa Kirin, Inc. | 2018-10-22 |
| Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis (NCT03293030) | University of California, San Francisco | 2018-10-22 |
| Early Origins of Allergy and Asthma (NCT04186949) | Pontificia Universidad Catolica de Chile | 2018-10-09 |
| Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (NCT03654755) | Asana BioSciences | 2018-09-29 |
| A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer (NCT03719742) | Burt's Bees Inc. | 2018-09-27 |
| In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control (NCT03441568) | Bayer | 2018-09-26 |
| Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (NCT03058783) | Bausch Health Americas, Inc. | 2018-08-14 |
| Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (NCT03569293) | AbbVie | 2018-08-13 |
| Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (NCT03556592) | LEO Pharma | 2018-08-13 |
| A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis (NCT03689829) | Lakefront Biotherapeutics NV | 2018-08-13 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03568318) | AbbVie | 2018-08-09 |
| Detection of Skin Epithelial Barrier in Patients With Allergic Skin Disorders (NCT03581747) | Swiss Institute of Allergy and Asthma Research | 2018-08-01 |
| Bone Health in Patients With Atopic Dermatitis (NCT03800004) | Mayo Clinic | 2018-07-30 |
| A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) (NCT03607422) | AbbVie | 2018-07-27 |
| A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis (NCT04110873) | Chung Shan Medical University | 2018-07-27 |
| Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301) (NCT03002571) | Bausch Health Americas, Inc. | 2018-07-24 |
| A Trial of Antroquinonol in Patients With Atopic Dermatitis (NCT03622463) | Golden Biotechnology Corporation | 2018-07-17 |
| A Community-based Assessment of Skin Care, Allergies, and Eczema (NCT03409367) | Oregon Health and Science University | 2018-07-16 |
| Scratch and Sleep Quantification in Atopic Dermatitis (NCT03490877) | University of Rochester | 2018-07-13 |
| Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (NCT03562377) | LEO Pharma | 2018-07-13 |
| A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis (NCT03585296) | Aclaris Therapeutics, Inc. | 2018-07-10 |
| Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) (NCT03568331) | Vanda Pharmaceuticals | 2018-07-09 |
| Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) (NCT03531957) | Asana BioSciences | 2018-07-05 |
| Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis (NCT03559075) | Wake Forest University Health Sciences | 2018-07-02 |
| A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (NCT03559270) | Eli Lilly and Company | 2018-06-27 |
| Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema (NCT03619161) | University of North Carolina, Chapel Hill | 2018-06-21 |
| Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients (NCT03571620) | Qurient Co., Ltd. | 2018-06-21 |
| Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). (NCT03526861) | LEO Pharma | 2018-06-19 |
| Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis (NCT03533751) | AnaptysBio, Inc. | 2018-06-19 |
| Vitamin D in Egyptian Children With Atopic Dermatitis (NCT04468711) | National Hepatology & Tropical Medicine Research Institute | 2018-06-06 |
| A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis (NCT03000595) | Santalis Pharmaceuticals, Inc. | 2018-06-01 |
| Study to Evaluate the Use of a Probiotic in SCORAD Reduction in Young Patients With Atopic Dermatitis (NCT03822624) | Biopolis S.L. | 2018-05-23 |
| A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis (NCT03496974) | Janssen Research & Development, LLC | 2018-05-21 |
| A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable (NCT03428100) | Eli Lilly and Company | 2018-05-15 |
| Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis (NCT03514511) | LEO Pharma | 2018-05-07 |
| Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis (NCT03388866) | Casa Espirita Terra de Ismael | 2018-05-02 |
| A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis (NCT03464526) | Nerre Therapeutics Ltd. | 2018-05-01 |